10X Capital Venture Acquisition Corp. III
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VCXB research report →
Price Chart
About the company
10X Capital Venture Acquisition Corp. III currently lacks notable business operations. Its core mission involves executing a business combination, which could entail a merger, an exchange of shares, an asset purchase, or a comprehensive reorganization with one or more companies or their assets.
- CEO
- David Weisburd
- IPO
- 2022
- Employees
- 4
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on VCXB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $146.06M
- P/E
- 553.50
- PEG
- -1.40
- P/S
- 0.00
- P/B
- 1.52
- EV/EBITDA
- -42.23
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 3.33%
- ROIC
- -1.13%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,463,223
- Net Income
- $4.86M+10994.7%
- EPS
- $0.02+1918.2%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $12.99
- 52W Low
- $10.52
- 50D MA
- $11.01
- 200D MA
- $10.81
- Beta
- 0.07
- RSI (14)
- 50
- Avg Volume
- 29.92K
No earnings-call transcripts are available for VCXB yet.
- Free Float
- 17.5%
- Shares Outstanding
- 13.19M
- Float Shares
- 2.31M
of shares held by institutions
12 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Spring Creek Capital LLC | 500.00K | ▲ 500.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 9, 24 | Ahmed Osman | other | 0 |
| Dec 8, 22 | Sheikh Kash | other | 0 |
| Dec 8, 22 | Sheikh Kash | other | 0 |
| Jan 14, 22 | 10X Capital SPAC Sponsor III LLC | other | 5,000 |
| Jan 11, 22 | 10X Capital SPAC Sponsor III LLC | other | 10,005,000 |
| Jan 11, 22 | Kandasamy Guhan | other | 0 |
| Jan 11, 22 | Jurasek Christopher | other | 0 |
| Jan 11, 22 | Levin Woodrow | other | 0 |
| Jan 11, 22 | 10X Capital SPAC Sponsor III LLC | other | 10,005,000 |
| Jan 11, 22 | Weisburd David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VCXB coverage
Recent articles, reports, and earnings notes.
No research on VCXB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VCXB report →NYSE American to Commence Delisting Proceedings with Respect to the Warrants of 10X Capital Venture Acquisition Corp. III (VCXB WS)
businesswire.com · Jun 25
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing
globenewswire.com · Apr 23
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Noncompliance
globenewswire.com · Jan 31
10X Capital Venture Acquisition Corp. III Announces Expected Change in Management
globenewswire.com · Jan 8
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
globenewswire.com · Nov 28
10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American
globenewswire.com · Oct 4
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
globenewswire.com · Aug 9
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III
globenewswire.com · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.